Abstract: Objective To investigate the expression of DNA excision repair cross-complementing gene 1（ERCC1）in local andvanced nasopharyngeal carcinoma， and to analyze the relationship between the expression of ERCC1 and the efficacy of concurrent radiochemotherapy in the treatment of nasopharyngeal carcinoma. Methods Seventy-six patients with none differentiated and the diversification nasopharyngeal carcinoma by nasopharyngeal neoplasm biopsy accepted single-agent cisplatin（DDP 80mg／m2， intravenous drip） concurrent chemoradiotherapy from January 2010 to December 2010. Radiation therapy was performed with the conventional segmentation illuminate 5/week on d1， d22， d43 with mean dose of 74Gy（70-78Gy） for nasopharyngeal. The curative effects were evaluated and the long-term survival was followed up. Immunohistochemistry was used to detect the ERCC1 protein expression in nasopharyngeal carcinoma tissue. The relationship between the expression of ERCC1 and the sensitivity of concurrent radiochemotherapy and long-term survival rate were analyzed. Results The positive rate of ERCC1 in 76 patients was 42.1％（32／76）. The expression of ERCC1 was related to the T classification and clinical stage（P＜0.05）， but not to gender， age and N staging. The response rates of the ERCC1 positive and negative patients were 75.0％ and 97.7％ with statistical significance（P＜0.05）. Of 72 follow-up cases， the 1-，2-and 3-year survival rates of all were 91.0％，83.3％ and 79.0％ and those for the ERCC1 negative and the positive patients were 92.4％， 87.8％， 80.5％ and 87.9％， 77.4％， 77.4％， respectively. The overall survival（OS） of ERCC1 positive and negative patients had no statistically significant difference（P＞0.05）. The medium OS of ERCC1 positive patients among different classification had statistically significant difference（P＜0.05）.
ConclusionThe ERCC1 expression may be a sensitive prognostic indicator of the concurrent radiochemotherapy in local advanced nasopharyngeal carcinoma.